Disease: Cancer-related depression

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

mycolabadmin

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

Read More »

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

mycolabadmin

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Read More »

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

mycolabadmin

This comprehensive review explores how psychedelic drugs like psilocybin mushrooms, DMT, and LSD may offer new hope for treating depression, anxiety, and PTSD, especially for patients who don’t respond to conventional antidepressants. Historically used in spiritual ceremonies for thousands of years, these compounds are now being scientifically studied and show promise with fewer side effects than many traditional psychiatric medications. The authors emphasize that while results are encouraging, more research and regulatory approval are needed before these treatments become widely available in mainstream medicine.

Read More »

Therapeutic and legal aspects of psilocybin in cancer-related depression

mycolabadmin

This paper examines how psilocybin, a naturally occurring psychoactive compound from mushrooms, could help cancer patients—especially those with head and neck cancer—who develop severe depression after surgery. Unlike traditional antidepressants that take weeks to work, psilocybin acts within hours, making it potentially ideal for patients needing rapid mental health support following disfiguring surgical procedures. However, while psilocybin is legal for medical or research use in several countries like Australia and Portugal, it remains restricted in Poland and many other places, creating legal barriers to its clinical implementation.

Read More »

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

mycolabadmin

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Read More »
Scroll to Top